Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction

The New England Journal of Medicine
Elliott M AntmanExTRACT-TIMI 25 Investigators

Abstract

Unfractionated heparin is often used as adjunctive therapy with fibrinolysis in patients with ST-elevation myocardial infarction. We compared a low-molecular-weight heparin, enoxaparin, with unfractionated heparin for this purpose. We randomly assigned 20,506 patients with ST-elevation myocardial infarction who were scheduled to undergo fibrinolysis to receive enoxaparin throughout the index hospitalization or weight-based unfractionated heparin for at least 48 hours. The primary efficacy end point was death or nonfatal recurrent myocardial infarction through 30 days. The primary end point occurred in 12.0 percent of patients in the unfractionated heparin group and 9.9 percent of those in the enoxaparin group (17 percent reduction in relative risk, P<0.001). Nonfatal reinfarction occurred in 4.5 percent of the patients receiving unfractionated heparin and 3.0 percent of those receiving enoxaparin (33 percent reduction in relative risk, P<0.001); 7.5 percent of patients given unfractionated heparin died, as did 6.9 percent of those given enoxaparin (P=0.11). The composite of death, nonfatal reinfarction, or urgent revascularization occurred in 14.5 percent of patients given unfractionated heparin and 11.7 percent of those given ...Continue Reading

References

Jan 1, 1986·The American Journal of Cardiology·A K GashR D Gentzler
Sep 2, 1993·The New England Journal of Medicine·UNKNOWN GUSTO investigators
Sep 12, 1996·The New England Journal of Medicine·UNKNOWN Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO) IIb investigators
Sep 4, 1997·The New England Journal of Medicine·J I Weitz
Oct 27, 1997·The New England Journal of Medicine·UNKNOWN Global Use of Strategies to Open Occluded Coronary Arteries (GUSTO III) Investigators
Oct 27, 1997·The New England Journal of Medicine·UNKNOWN Continuous Infusion versus Double-Bolus Administration of Alteplase (COBALT) Investigators
May 23, 2001·Circulation·E M Antman
Feb 1, 2003·European Heart Journal·Frans Van de WerfUNKNOWN Task Force on the Management of Acute Myocardial Infarction of the European Society of Cardiology

❮ Previous
Next ❯

Citations

Aug 18, 2006·Der Anaesthesist·V WenzelUNKNOWN European Resuscitation Council
Feb 12, 2009·Clinical Research in Cardiology : Official Journal of the German Cardiac Society·Nicolas MeneveauJean-Pierre Bassand
Mar 17, 2010·Wiener medizinische Wochenschrift·Serdar FarhanKurt Huber
Dec 25, 2009·Cardiovascular Drugs and Therapy·Elias B HannaJorge F Saucedo
Mar 26, 2011·Cardiovascular Drugs and Therapy·Amelia CarroJuan Carlos Kaski
Jan 16, 2007·Journal of Thrombosis and Thrombolysis·Jonathan D RichChristopher P Cannon
Oct 22, 2008·Journal of Thrombosis and Thrombolysis·Deepak Thomas, Robert P Giugliano
Mar 14, 2009·Journal of Thrombosis and Thrombolysis·Frederick LeriJohn Guzek
Jan 22, 2010·Journal of Thrombosis and Thrombolysis·S Michael GharacholouJohn H Alexander
Mar 1, 2012·Journal of Thrombosis and Thrombolysis·Robert C WelshPaul W Armstrong
May 9, 2012·Journal of Thrombosis and Thrombolysis·S Michael GharacholouAmish N Raval
Nov 4, 2008·Internal and Emergency Medicine·Giovanni MelandriAngelo Branzi
Oct 23, 2012·Current Treatment Options in Cardiovascular Medicine·Charles V Pollack
Feb 23, 2010·JACC. Cardiovascular Interventions·Gilles MontalescotUNKNOWN Facilitated INtervention with Enhanced Reperfusion Speed to Stop Events Investigators
Jun 30, 2010·International Journal of Technology Assessment in Health Care·Edmundas KaduseviciusDanguole Jankauskiene
May 27, 2006·Nature Clinical Practice. Cardiovascular Medicine·A Michael Lincoff
Oct 27, 2006·Nature Clinical Practice. Nephrology·Jean-Philippe Collet, Gilles Montalescot
Jun 30, 2006·The New England Journal of Medicine·Douglas D DeCarolis
Mar 16, 2006·The New England Journal of Medicine·Raymond J Gibbons, Valentin Fuster
Apr 21, 2006·The New England Journal of Medicine·Stephen W Lagakos
Jun 8, 2010·Surgical Infections·John C MarshallMitchell Levy
Jun 8, 2010·European Heart Journal·Peter Sinnaeve, Frans Van de Werf
Mar 26, 2009·European Journal of Emergency Medicine : Official Journal of the European Society for Emergency Medicine·Patrick GoldsteinJean Michel Juliard
Oct 19, 2007·International Journal of Clinical Practice·M CohenF Kuepper
Dec 7, 2007·Postgraduate Medical Journal·J B Jones, A Docherty
May 10, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Paul W ArmstrongUNKNOWN ASSENT-3 and ASSENT-3 PLUS Investigators
May 10, 2006·CMAJ : Canadian Medical Association Journal = Journal De L'Association Medicale Canadienne·Alison L Bailey, Steven R Steinhubl
Feb 28, 2007·Vascular Health and Risk Management·Alexander G G Turpie

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.